Ann: PTX-100 clinical data presented at leading TCL meeting, page-8

Its probably worthwhile noting that the patient still in complete response to receive ongoing PTX-100 treatment under the compassionate access scheme, has (or rather did) have PTCL. I get the impression that PTCL (being the problem child of TCL) is the subset of TCL which would most benefit from a successful targeted drug like PTX-100 in a combo therapy. There is a chance that if early data readouts for our Ph2 CTCL trial are good, then the race will be on to pursue a partner to take PTX-100 into a Phase 2 trial also. That's my belief. Maybe @logan123 could share his thoughts on this.